BioPharmSignal logoBioPharmSignal

Biotech News

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Exagen (XGN)Exagen2026-06-25 13:46 ESTEarnings

Record full-year total revenue and AVISE ® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported

Open original release

Related news

XGNExagen2026-06-25 13:46 EST

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

XGNExagen2026-06-25 13:46 EST

Exagen Inc. Reports First Quarter 2026 Results

XGNExagen2026-06-25 13:46 EST

Exagen Inc. to Participate in Third Quarter Investor Conferences

XGNExagen2026-06-25 13:46 EST

Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025

XGNExagen2026-06-25 13:46 EST

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

XGNExagen2026-06-25 13:46 EST

Exagen Inc. Reports Strong Q3 2025 Results

XGNExagen2026-06-25 13:46 EST

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

XGNExagen2026-06-25 13:46 EST

Exagen Inc. Announces Select Preliminary 2025 Financial Results

XGNExagen2026-06-25 13:46 EST

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

XGNExagen2026-06-25 13:46 EST

Exagen Inc. to Participate in Upcoming Investor Conferences

View all latest news

Exagen

Exagen is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

XGNExagen2026-06-26 13:21 EST

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

XGNExagen2026-06-26 13:21 EST

Exagen Inc. Reports First Quarter 2026 Results

XGNExagen2026-06-26 13:21 EST

Exagen Inc. to Participate in Third Quarter Investor Conferences

XGNExagen2026-06-26 13:21 EST

Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025

XGNExagen2026-06-26 13:21 EST

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States